Policy & Regulation
Shattuck Labs welcomes Casi DeYoung as CBO
10 December 2019 -

Biotechnology company Shattuck Labs Inc revealed on Monday the addition of Casi DeYoung as its chief business officer.

Most recently, DeYoung has served as the chief operating officer at ImmuneSensor Therapeutics, with responsibility for corporate strategy, start-up operations, intellectual property, oversight of its first IND filing and the initiation of a first-in-human Phase 1 clinical trial.

Previously, DeYoung was employed as chief business officer at Mirna Therapeutics as well as operations director for oncology at EMD Pharmaceuticals and Merck KGaA.

Earlier in her career, DeYoung has worked as vice president of business development at Reata Pharmaceuticals as well as ODC Therapy